Biologics Manufacturing Processing Steps - Upstream and Downstream Operations
Biologics are among the most operationally complex therapies manufactured in the pharmaceutical industry. Unlike traditional small molecule drugs synthesized through chemical reactions, biologics are produced using living cells under tightly controlled conditions.
While this article focuses on monoclonal antibody biologics manufacturing using CHO cells, advanced therapies such as autologous and allogeneic cell therapies introduce additional operational complexity related to chain of identity, chain of custody, patient-specific manufacturing, and cryogenic logistics. You can learn more in our overview of Cell Therapy Manufacturing.
Monoclonal antibodies (mAbs), recombinant proteins, and many advanced biologic therapies rely on mammalian cell culture systems capable of producing highly specific therapeutic proteins.
Modern biologics manufacturing facilities are designed to support these highly controlled production environments while maintaining product quality, sterility assurance, and process consistency. Because living systems are inherently variable, biologics manufacturing requires extensive process control, environmental monitoring, contamination prevention, and GMP oversight to ensure product quality and patient safety.
This article provides a practical overview of biologics manufacturing using Chinese Hamster Ovary (CHO) cells — the most widely used mammalian expression system in commercial antibody production.
A typical biologics manufacturing process can generally be divided into two major manufacturing phases:
- Upstream Cell Culture Manufacturing:
growing and maintaining cells that produce the therapeutic protein - Downstream Purification:
purifying, concentrating, and filling the drug product for patient use
For organizations operating GMP manufacturing facilities, each unit operation introduces potential operational risk, process variability, and Cost of Poor Quality (COPQ) exposure that must be actively managed through governance, quality systems, and disciplined execution.
What Is a Biologic?
Biologics are therapeutic products manufactured using living systems such as mammalian cells, bacteria, yeast, or other biological platforms. Common biologics include monoclonal antibodies, vaccines, recombinant proteins, and cell and gene therapies.
Unlike chemically synthesized drugs, biologics are highly sensitive to manufacturing conditions. Small changes in temperature, pH, nutrient availability, agitation, or contamination can alter protein structure, glycosylation profiles, aggregation behavior, or product purity.
Because the manufacturing process directly impacts the final product, biologics manufacturing requires:
- Tight process control
- Extensive analytical characterization
- Robust contamination control strategies
- Validated cleaning and sterilization systems
- Strong GMP quality systems
- Cross-functional operational governance
This operational sensitivity is one reason biologics manufacturing environments are heavily monitored and highly proceduralized.
Overview of the Biologics Manufacturing Process
A typical monoclonal antibody manufacturing process follows this general flow:
- Cell banking
- Vial thaw and cell expansion
- Seed train scale-up
- Production bioreactor
- Harvest and clarification
- Protein purification
- Viral clearance
- Concentration and formulation
- Bulk drug substance storage
- Aseptic fill finish
Cell Banking: The Foundation of Manufacturing
Before commercial manufacturing begins, a stable cell line capable of producing the target antibody must be developed and preserved.
This begins with creation of a:
- Master Cell Bank (MCB)
- Working Cell Bank (WCB)
The Master Cell Bank serves as the primary long-term source of genetically characterized cells. Working Cell Banks are generated from the MCB and used operationally to support manufacturing campaigns.
Cell banking activities are critical because they establish:
- Genetic consistency
- Product reproducibility
- Traceability
- Manufacturing continuity
- Long-term process stability
Cell banks are typically stored cryogenically under highly controlled conditions with extensive characterization testing performed to evaluate:
- Sterility
- Mycoplasma
- Adventitious agents
- Identity
- Viability
- Productivity
- Genetic stability
Because contamination or instability at the cell bank level can impact every future manufacturing batch, cell banking is often considered one of the foundational control points in biologics manufacturing.
Upstream Manufacturing Operations in Biologics Manufacturing
Upstream manufacturing focuses on expanding mammalian cells and creating the conditions required for therapeutic protein production.
In commercial monoclonal antibody manufacturing, CHO cells are commonly used because they are well understood, scalable, and capable of generating human-compatible protein modifications.
The upstream process typically consists of several sequential expansion stages collectively referred to as the seed train.
Vial Thaw
Manufacturing begins by thawing a frozen vial from the Working Cell Bank.
This operation is typically performed under aseptic conditions within a biological safety cabinet or laminar airflow hood.
The goal of vial thaw is to recover viable cells while minimizing:
- Thermal stress
- Osmotic shock
- Contamination risk
- Cell damage
Following thaw, cells are transferred into growth media containing nutrients, amino acids, vitamins, sugars, and growth factors required to support cellular recovery and proliferation.
Although operationally simple, vial thaw represents a high-consequence step because contamination or poor recovery can compromise the entire manufacturing campaign.
Shake Flask Expansion
Following recovery, cells are expanded in shake flasks.
These flasks provide a controlled environment for early-stage biomass generation while allowing operators and process scientists to evaluate:
- Cell viability
- Growth rate
- Morphology
- Metabolic performance
- Contamination indicators
Agitation within the flask promotes oxygen transfer and nutrient mixing while maintaining cells in suspension.
At this stage, process consistency becomes important because variability introduced early in the expansion process can amplify during large-scale manufacturing.
Seed Train Expansion (N-3, N-2, N-1)
As cell density increases, the culture is transferred through progressively larger bioreactors in a sequence commonly referred to as the seed train.
Typical stages include:
- N-3 bioreactor
- N-2 bioreactor
- N-1 bioreactor
- Production bioreactor (N stage)
Each transfer increases culture volume while maintaining cell health and productivity.
Critical process parameters (CPPs) commonly controlled during seed train operations include:
- Temperature
- pH
- Dissolved oxygen (DO)
- Agitation speed
- Gas flow rates
- Osmolality
- Nutrient feed strategy
The seed train is operationally important because it determines the health and readiness of the final production inoculum.
Failures during scale-up can result in:
- Reduced productivity
- Delayed manufacturing campaigns
- Contamination events
- Batch loss
- Capacity constraints
For this reason, upstream operations often require close coordination between manufacturing, process science, engineering, and quality organizations.
Production Bioreactor (N Stage)
The production bioreactor is the primary manufacturing stage where cells produce the therapeutic antibody.
Commercial production bioreactors may range from several hundred liters to over 20,000 liters depending on manufacturing scale and facility design.
Most monoclonal antibody processes operate in fed-batch mode, where nutrients are added throughout the production run to support extended cell growth and protein expression.
During production, cells are highly sensitive to process conditions. Variability in:
- pH
- Temperature
- Dissolved oxygen
- Nutrient availability
- Agitation
- Gas transfer
can impact:
- Protein yield
- Glycosylation patterns
- Aggregation behavior
- Product quality attributes
Modern facilities frequently utilize process analytical technology (PAT), automated control systems, and real-time monitoring to maintain process stability.
Operationally, production bioreactors represent one of the highest-value assets in biologics manufacturing. Extended downtime, contamination events, or failed batches can generate significant Cost of Poor Quality (COPQ) exposure due to:
- Lost production capacity
- Delayed supply
- Investigation burden
- Deviation management
- Raw material loss
- Labor inefficiency
Harvest and Clarification
Once the production phase is complete, the cell culture must be harvested to separate the therapeutic protein from cells and process impurities.
Harvest operations typically include:
- Centrifugation
- Depth filtration
- Clarification filtration
These steps remove:
- Whole cells
- Cell debris
- Insoluble particulates
- Process contaminants
The clarified harvest material contains the target antibody along with residual impurities such as host cell proteins, DNA, media components, and process-related contaminants.
Many manufacturing processes also incorporate low pH viral inactivation shortly after harvest as part of the overall viral clearance strategy.
Harvest and clarification operations are important because poor clarification performance can negatively impact downstream filtration throughput, chromatography performance, and overall process robustness.
Downstream Manufacturing Operations in Biologics Manufacturing
After harvest, manufacturing focus shifts from growing cells to purifying the therapeutic protein.
Downstream manufacturing consists of multiple purification and polishing steps designed to remove process impurities while maintaining protein stability and biological activity.
Typical impurities removed during downstream processing include:
- Host cell proteins (HCP)
- Residual DNA
- Aggregates
- Media components
- Endotoxin
- Viral contaminants
- Process-related impurities
Low pH Viral Inactivation
To reduce viral contamination risk, monoclonal antibody processes commonly include a dedicated low pH viral inactivation step.
During this operation, the product pool is temporarily exposed to acidic conditions capable of inactivating enveloped viruses.
Critical parameters include:
- Target pH
- Hold time
- Temperature
- Mixing consistency
This step is tightly controlled because excessive exposure can negatively impact protein stability while insufficient exposure may reduce viral clearance effectiveness.
Viral clearance strategies are a critical regulatory expectation in commercial biologics manufacturing.
Protein A Chromatography
Protein A chromatography is commonly the first major purification step in monoclonal antibody manufacturing.
Protein A resin selectively binds the Fc region of antibodies, allowing impurities to flow through while the target antibody is captured.
Following binding, the column is washed to remove residual impurities before the antibody is eluted under controlled conditions.
Protein A chromatography provides:
- High selectivity
- Significant impurity reduction
- Early process concentration
However, Protein A operations also introduce operational considerations including:
- Resin fouling
- Ligand leaching
- Column lifetime management
- Cleaning validation
- Pressure excursions
- Throughput limitations
Because chromatography resins are expensive and operationally critical, chromatography performance often becomes a major focus area for manufacturing optimization and COPQ reduction.
Polishing Chromatography
Following initial capture, additional chromatography steps are used to further purify the antibody and remove residual impurities.
Common polishing methods include:
- Ion exchange chromatography (IEX)
- Hydrophobic interaction chromatography (HIC)
- Mixed-mode chromatography
These steps may target removal of:
- Aggregates
- Host cell proteins
- DNA
- Charge variants
- Product fragments
Polishing chromatography is often highly process-specific and may require extensive optimization to balance:
- Yield
- Purity
- Throughput
- Resin utilization
- Process robustness
Viral Filtration
Viral filtration uses nanofiltration membranes designed to remove potential viral contaminants from the product stream.
These filters operate based on highly controlled pore sizes capable of retaining viral particles while allowing antibodies to pass through.
Operational considerations include:
- Filter fouling
- Differential pressure
- Flux decay
- Throughput limits
- Protein aggregation risk
Because viral filtration systems are sensitive to feed stream quality, upstream purification performance can significantly impact filtration robustness.
Tangential Flow Filtration (TFF)
Tangential Flow Filtration (TFF) is commonly used to:
- Concentrate the product
- Exchange buffers
- Prepare the formulation for storage or fill finish
Unlike dead-end filtration, TFF flows parallel to the membrane surface, helping reduce fouling and maintain filtration efficiency.
TFF systems may perform:
- Ultrafiltration (UF)
- Diafiltration (DF)
Critical operational parameters include:
- Transmembrane pressure
- Crossflow rate
- Protein concentration
- Shear exposure
- Membrane performance
Because monoclonal antibodies can be sensitive to shear and aggregation, TFF process control is important for maintaining product quality.
Bulk Drug Substance (BDS) Storage
Following purification and formulation, the product is commonly stored as Bulk Drug Substance (BDS).
BDS storage may involve:
- Frozen storage
- Refrigerated storage
- Single-use containers
- Stainless steel vessels
- Controlled shipping systems
Operational focus areas include:
- Hold time management
- Temperature monitoring
- Container closure integrity
- Cold chain logistics
- Product stability
At this stage, the product has typically achieved its required purity profile but has not yet been filled into final patient-ready containers.
